Equities research analysts at Leerink Partners assumed coverage on shares of Elanco Animal Health (NYSE:ELAN – Get Free ...

Investment analysts at Leerink Partners began coverage on shares of Zoetis (NYSE:ZTS – Get Free Report) in a note issued to ...

Fintel reports that on December 2, 2024, Leerink Partners initiated coverage of Zoetis (NYSE:ZTS) with a Outperform ...

Fintel reports that on December 2, 2024, Leerink Partners initiated coverage of IDEXX Laboratories (NasdaqGS:IDXX) with a ...

On Monday, Zoetis Inc (ZTS) stock saw a modest uptick, ending the day at $176.81 which represents a slight increase of $1.56 or 0.89% from the prior close of $175.25. The stock opened at $175.78 and ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

AbbVie (ABBV) shares jump after Leerink Partners upgraded the stock to Outperform, saying the recent sell-off creates an ...

AbbVie shares rose after a Leerink Partners analyst upgraded the stock's rating to outperform. The improved rating comes ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

Leerink Partners analyst Mike Kratky maintained a Buy rating on Insulet (PODD – Research Report) on November 25 and set a price target of ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating on November 29.Don't Miss our ...